Sodium-glucose co-transporter 2 (sglt-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (hf) with reduced ejection fraction with recent trials suggesting a significant … Abstract background heart failure (hf) is a clinical diagnosis of a condition that develops secondary to either left ventricular systolic or diastolic functions. Lately, inhibitors of sodium-glucose cotransporter …

Dapagliflozin and empagliflozin have shown benefits in patients with hfref, hfpef, and hfmref with or without diabetes. 7 sglt2 … Heart failure - chronic: Sodium-glucose cotransporter-2 (sglt2) inhibitor last revised in september 2025 dose start dapagliflozin or empagliflozin on the advice of a heart failure specialist. The acc’s heart failure and sglt2is: The new pillar in care initiative is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 inhibitors (sglt2i) …

The new pillar in care initiative is designed to provide practical guidance for clinicians on the implementation of sodium-glucose cotransporter-2 inhibitors (sglt2i) …